Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousand yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The numbers of initial consultations, total consultations and surgeries increased as clinical capacity was strengthened, and the number of affiliated hospitals also rose. The number of rental contracts increased as a result of sales initiatives, while the benefit of higher revenue, the impact of price revisions in the previous fiscal year and ongoing productivity improvement initiatives contributed to profit.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥3,367 million (YoY +11.0%) |
| Operating profit | ¥725 million (YoY +22.8%) |
| Ordinary income | ¥713 million (YoY +21.0%) |
| Profit attributable to owners of the parent | ¥489 million (YoY +18.4%) |
| Net income per share | ¥37.86 |
| Equity ratio | End of the current fiscal period 46 / End of previous period 43.1 |
| Total assets | ¥11,318 million |
| Net assets | ¥5,207 million |
| Cash flows from operating activities | 613,071 Thousand yen |
| Cash flows from investing activities | -748,870 Thousand yen |
| Cash flows from financing activities | -336,131 Thousand yen |
| Cash and cash equivalents at end of period | 1,120,955 Thousand yen |
| Full-year earnings forecast | Net Sales ¥6,600 million (YoY +6.6%) / Operating profit ¥1,270 million (YoY +10.4%) / Ordinary income ¥1,220 million (YoY +6.8%) / Profit attributable to owners of the parent ¥890 million (YoY +6.8%) |
| Annual Dividend Forecast | 12 Yen → 13 Yen |
| Depreciation and amortization | 240,140 Thousand yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of fixed assets 826 Thousand yen / Extraordinary loss Loss on sale of non-current assets 45 Thousand yen |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | No material changes (0 entities added or excluded) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 14,391,000 |
| Treasury Shares at Period-End | 1,465,940 |
| Factors Behind Changes in Business Performance | The numbers of initial consultations, total consultations and surgeries increased as clinical capacity was strengthened, and the number of affiliated hospitals also rose. The number of rental contracts increased as a result of sales initiatives, while the benefit of higher revenue, the impact of price revisions in the previous fiscal year and ongoing productivity improvement initiatives contributed to profit. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The number of consultations increased as clinical capacity was strengthened, while the number of rental contracts also increased as a result of sales initiatives. In addition to the benefit of higher revenue, the impact of price revisions implemented in the previous fiscal year and ongoing productivity improvement initiatives contributed to profit. A review of useful lives also increased operating profit and other items by ¥48.855 million.